We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tahlita Zuiverloon

Tahlita Zuiverloon MD, PhD

Research fellow, University of Colorado Comprehensive Cancer Center

Tahlita Zuiverloon MD PhD is a young urologist at Erasmus University Rotterdam, in the Netherlands and currently a research fellow in the laboratory of Dr. Dan Theodorescu at the University of Colorado Comprehensive Cancer Center. Zuiverloon finished her training as a biomedical scientist and urologist at Leiden University in the Netherlands. She contributed to the development of urine-based FGFR3 mutation and methylation detection assays for the surveillance of NMIBC patients. These assays are currently being tested in a national randomized controlled trial in the Netherlands. Zuiverloon’s current research efforts are focused on the identification of biomarkers predicting response to intravesical BCG instillations and on predictors of neoadjuvant chemotherapy.


No relevant disclosures reported.